text:
eNewsletter Sign Up Advertise & Update Listings Order Advocacy Connector Cards Login ORDER GUIDES
PHYSICIAN CHAMPION
READER SURVEY WINNERS
TEN THINGS YOU SHOULD KNOW
MAKING A PLAN
SCREENING AND STAGING
UNDERSTANDING IMMUNOTHERAPY
UNDERSTANDING RADIATION THERAPY
FINDING YOUR MEDICAL TEAM
SEEKING A SECOND OPINION
WHY CLINICAL TRIALS
GENOMIC AND GENETIC TESTING
TUMOR BIOMARKERS
BASIC CANCER TERMS
ANAL CANCER
BREAST CANCER ADVANCED
BREAST CANCER HER2+
BREAST CANCER TRIPLE NEGATIVE
CANCER OF UNKNOWN PRIMARY
LYMPHOMAS
METASTATIC DISEASE
MYELOFIBROSIS
PROSTATE CANCER ADVANCED
RENAL CELL CARCINOMA
JOURNEYS / SURVIVORSHIP
FEATURED SURVIVORS
EARLY MENOPAUSE
NUTRITION CHALLENGES
OTHER SIDE EFFECTS
CANCER CENTERS BY STATE
BREAST CENTERS BY STATE
BONE MARROW TRANSPLANT CENTERS
WHAT IS RIGHT FOR YOU
NCI DESIGNATED CANCER CENTERS
FINANCIAL & ADVOCACY RESOURCES
PATIENT AND CAREGIVER RESOURCES
PATIENT MATCHING SERVICES
FINDING CAREGIVERS AND COUNSELORS
TALKING WITH YOUR KIDS
TALKING WITH YOUR EMPLOYER
MAXIMIZING INSURANCE
ORGANIZING YOUR PAPERWORK
PATIENT ADVOCATE INTERVIEW
PREDICTING RECURRENCE
SELF ADVOCACY
TALKING TO YOUR PHARMACIST
PATIENT MARKETPLACE
Patient Resource has assembled a prestigious Advisory Board to assist with editorial focus and ensure accuracy of the information presented. Members include well-known names from business and industry, opinion leaders from non-profit organizations, and highly respected medical doctors from the nation's leading cancer treatment facilities. Editor-in-Chief is Charles M. Balch, MD, FACS, who oversees a team of seasoned medical writers to ensure editorial content is both accurate and engaging and presented with a sensitive professionalism meant to empower cancer patients and their families.
Dr. Balch's Award Video
Dr. Charles Balch was previously honored with the Gold T Award in recognition of outstanding achievement in his field by The University of Toledo.
View his featured award video here.
Charles M. Balch, MD, FACS, FASCO
Professor of Surgery, The University of Texas MD Anderson Cancer Center
Editor-in-Chief, Patient Resource LLC
Former Executive Vice President & CEO, American Society of Clinical Oncology
Past President, Society of Surgical Oncology
Dr. Charles M. Balch, oncologist, surgeon, and one of the world's preeminent melanoma and breast cancer experts, has devoted more than 40 years to trailblazing research and to leadership positions in academic and clinical settings. Dr. Balch is a renowned teacher and lecturer and a revered mentor in the field of surgery and oncology. He currently serves as professor of surgery at the University of Texas MD Anderson Cancer Center in Houston and as editor-in-chief of Patient Resource Cancer Guides.
Dr. Balch has led global efforts to build networks in the areas of outcomes research and clinical trials, authoring more than 750 publications on clinical investigations involving staging and prognostic factors in melanoma, standards of surgical treatment in melanoma and breast cancer, and the conduct and methodology of clinical research and immunology. His laboratory research accomplishments include significant contributions in tumor immunology and human T lymphocyte differentiation. His scientific publications have been cited in the biomedical literature in more than 23,000 articles, and he has lectured in more than 42 countries and most major U.S. academic centers.
Dr. Balch previously chaired the Melanoma Staging Committee of the American Joint Committee on Cancer (AJCC). He is editor of Cutaneous Melanoma, the authoritative textbook on melanoma, now in its fifth edition. He is the founding editor-in-chief of the Annals of SurgicalOncology and Breast Diseases (emeritus).
Dr. Balch most recently served at the University of Texas Southwestern Medical Center in Dallas as professor of surgery and before that at Johns Hopkins Medical Center as professor of surgery, oncology and dermatology; deputy director for clinical trials and outcomes research; and director of the Johns Hopkins Clinical Research Network. He earlier fulfilled similar duties at UT M. D. Anderson Cancer Center, The City of Hope National Medical Center, and the University of Alabama at Birmingham.
As Melanoma Staging Committee chair, Dr. Balch and other experts organized the largest prognostics factors analysis ever conducted. The study involved 60,000 melanoma patients from three continents and major cancer cooperative groups. Their analyses extensively revised the staging system for melanoma. Dr. Balch's contributions to the melanoma literature comprise six books and nearly 200 book chapters and articles relating to his clinical investigations. He has been a principal investigator of numerous clinical trials, many of them NCI-funded National Phase III trials, and has assumed key roles internationally in randomized surgical trials. The results of these trials have defined current melanoma surgery standards and established the safety of using more conservative surgical excision of primary melanoma. Additionally, he has led five cooperative clinical trials involving combinations of adjuvant biological therapy or chemotherapy in high-risk melanoma patients.
In the area of breast cancer, Dr. Balch was a co-principal investigator in the only randomized surgical trial comparing Halsted radical mastectomy with modified radical mastectomy. He helped pioneer skin saving mastectomies followed by immediate breast reconstruction. His immunology research has included participation in fundamental work delineating human T lymphocyte and NK cell differentiating surface markers, and in developing the anti-HNK1 monoclonal antibody that fi rst identifi ed the CD57 antigen on NK cells. Dr. Balch has served in various administrative and leadership positions with the American Society of Surgical Oncology (president), the American Board of Surgery (board of directors), the Association of Academic Surgeons (president), the Commission on Cancer (chair, board of directors), and the AJCC (executive committee). Recent honors include an honorary PhD from the University of Crete and the Highest Alumni Award from the University of Toledo, where he graduated with a BS in biology. He earned his MD from Columbia University College of Physicians and Surgeons.
U.S. Medical Advisory Board Members:
James O. Armitage, MD
The Joe Shapiro Professor of Medicine, Division of Oncology/Hematology,
Past President, American Society of Clinical Oncology
Past President, American Society for Blood and Marrow Transplantation
Dr. James O. Armitage is a graduate of the University of Nebraska Medical Center, completed his internship and residency in internal medicine at Nebraska, a fellowship in hematology oncology at the University of Iowa and a brief stint in private practice in Omaha. He developed and directed the Bone Marrow Transplant program at the University of Iowa and later at the University of Nebraska. He served as Vice-Chair of Internal Medicine, Chair of Internal Medicine, Dean of the College of Medicine and currently is The Joe Shapiro Professor of Medicine at the University of Nebraska Medical Center. Dr. Armitage is board certified in internal medicine, medical oncology and hematology, a Fellow of both the American and Royal College of Physicians, a past member of the National Cancer Advisory Board, past president of the American Society of Clinical Oncology and American Society for Blood and Marrow Transplantation. He is married and the father of four children and four grandchildren.
Lisa A. Newman, MD, MPH, FACS, FASCO
Chief, Division of Breast Surgery,
Director of Interdisciplinary Breast Program,
Weill Cornell Medicine, NewYork-Presbyterian Hospital Network
Medical Director, International Center for the Study of Breast Cancer Subtypes
Dr. Lisa A. Newman is chief of the division of breast surgery and director of the interdisciplinary breast program at Weill Cornell Medicine, NewYork-Presbyterian Hospital Network and serves as medical director of the International Center for the Study of Breast Cancer Subtypes at Henry Ford Health System. Previously she was director of the Breast Oncology Center at Henry Ford Health System. She received her medical degree from the State University of New York Health Science Center at Brooklyn. Dr. Newman completed her fellowship in surgical oncology at the MD Anderson Cancer Center and received her Masters Degree in Public Health from Harvard University.
She is internationally known for her research on ethnicity-related variation in breast cancer risk, including the biologic and genetic origins of triple negative breast cancer which is the focus of her ongoing work in Ghana.
In addition to leading a team at the forefront of breast cancer research and treatment at Henry Ford, she is the Chief National Medical Advisor for the Sisters Network Inc., and actively promotes collaborative breast cancer research through roles at the University of Texas M.D. Anderson Cancer Center and University of Michigan School of Public Health.
She holds leadership positions in the most prominent of cancer academic and advocacy organizations including the American College of Surgeons and the American Cancer Society, most recently receiving the distinction of Komen Scholar.
J. Max Austin Jr., MD
Professor Emeritus of Gynecologic Oncology, Department of Obstetrics and Gynecology, UAB Medical Center
Past President, Society of Gynecologic Oncologists
As a young man, J. Max Austin, Jr., M.D. left his home town of Wetumpka, Alabama to attend Georgia's Emory University. Four years and a bachelor's degree later he came back to his home state, earning a medical degree at the Medical College of Alabama in 1967. Except for a year out of the state for residency training and two years in the Air Force, Austin has been in Alabama ever since.
Dr. Austin has practiced gynecologic oncology and taught residents and fellowship students in this state throughout his career. Indeed, the state of Alabama-and treating its female cancer patients-are very dear to his heart.
Dr. Austin did his first year of residency in Atlanta in 1968-69, then he finished his OB/GYN residency and fellowship in Alabama. Having progressed along the academic ladder, he is now a full professor at the UASOM. He also founded Southern Gynecology, a private practice in Birmingham, and practiced there 22 years.
When Dr. Austin returned to the UASOM in 2000, the University of Alabama Health Services Foundation and the Department of Obstetrics and Gynecology established the J. Max Austin, Jr., M.D. Endowed Chair in Gynecologic Oncology in honor of his contributions to medicine and medical education in Alabama.
"There are some counties in Alabama that are equivalent to third-world countries in the death rates from cervical cancer, "he says. "This is tragic. We need to continue to educate, to teach the latest techniques in detection and diagnosis of gynecologic malignancies because many of them are potentially treatable if diagnosed early."
John E. Niederhuber, MD
Former Executive Vice President, Inova Health System
Chairman, Konica Minolta Scientific Advisory Board
Past President, Association of American Cancer Institutes
Past Director, National Cancer Institute
Dr. John Niederhuber is a nationally renowned surgeon and researcher with a clinical emphasis on gastrointestingal, hepatobiliary and breast cancers. He is recognized for his pioneering work in hepatic artery infusion chemotherapy. Dr. Niederhuber has been a long-time external advisor to the National Cancer Institute and has authored and coauthored more than 180 publications and edited four books.
Dr. Niederhuber recently joined Inova Health System as Executive Vice President and CEO of the Inova Translational Medical Institute. Prior to that, he served as Director of the National Cancer Institute, one of the National Institutes of Health from 2006 until July, 2010. During his tenure as NCI director, Dr. Niederhuber shaped the Nation's investment in cancer to address areas that are likely to pay the largest health dividends. He began The Cancer Genome Atlas, an effort to comprehensively identify the genomic changes in all major cancer types and subtypes. In addition to genomic studies of cancer and work in cancer immunotherapy, programs in nanobiology, systems biology, investigations into the tumor microenvironment, cancer initiating cells, and subcellular imaging have benefited under his direction. Dr. Niederhuber is recognized by his peers as a visionary leader in oncology. He daily puts into practice his expertise as both a cancer physician and a basic research scientist. His colleagues have acknowledged his leadership and accomplishments by electing him vice president and president of the Society for Surgical Oncology and president of the Association of American Cancer Institutes. He has served as a member of C-Change (a community of executives from government, business and non-profit communities dedicated to conquering cancer) and as a member of the CEO Roundtable on Cancer. Dr. Niederhuber is a member of the Institute of Medicine of the National Academy of Sciences, recognizing his outstanding scientific accomplishments and commitment to service in health sciences.
Al B. Benson III, MD, FACP, FASCO
Professor of Medicine, Associate Director for Cooperative Groups, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Past President, Association of Community Cancer Centers
Al B. Benson III, MD, is a professor of medicine in the Division of Hematology/Oncology at Northwestern University's Feinberg School of Medicine in Chicago. He is also the associate director for cooperative groups at the Robert H. Lurie Comprehensive Cancer Center, a National Cancer Institute-designated comprehensive cancer center, at Northwestern University. In addition, he is an attending physician at Northwestern Memorial Hospital, a staff physician at Jesse Brown VA Medical Center, and a consultant to the Rehabilitation Institute of Chicago.
Dr. Benson earned his medical degree at the University at Buffalo, The State University of New York, following which he completed an internal medicine residency at the University of Wisconsin Hospital and Clinics in Madison, Wis. He was an assistant professor of medicine at the University of Illinois and co-medical director for the National Public Health Service in Champaign, Ill. He then served as a clinical oncology and research fellow at the University of Wisconsin Clinical Cancer Center, where he received an American Cancer Society Fellowship Award.
Dr. Benson is active on numerous professional committees, often serving as an officer. He is a recipient of the American Society of Clinical Oncology (ASCO) Statesman Award (Fellow of ASCO) and has served on a number of committees. He has been a member of the Task Force on Quality of Cancer Care, the co-chair of ASCO's Colorectal Cancer Guidelines Subcommittee, the Stage II Colon Cancer Guidelines Panel and the Guidelines Panel for Use of Radiofrequency Ablation for Colorectal Cancer Hepatic Metastases. He also is the chair of both the Eastern Cooperative Oncology Group Gastrointestinal and Data Monitoring Committees and a member of the NCI GI Steering Committee. In addition, he is a past president of the Illinois Medical Oncology Society, past president of the Association of Community Cancer Centers (ACCC), an executive committee member and immediate past-chair of the Board of Directors of the National Comprehensive Cancer Network (NCCN) and a member of the Board of Directors of the NCCN Foundation. He is the chair of both the NCCN Hepatobiliary Guidelines Panel and of the Colon, Rectal and Anal Panel, and a member of the Pancreatic Cancer and Neuroendocrine Panels. He is also a past president of the International Society of GI Oncology (ISGIO). Dr. Benson is a member of the Scientific Board of Directors of the Patient Advocate Foundation, the National Patient Advocate Foundation and Friends of Cancer Research.
He is on the editorial board of the ASCO Connection, American Health and Drug Benefits, Personalized Medicine in Oncology, Journal of Comparative Effectiveness Research and Gastrointestinal Cancer Research, among others.
His most recent national awards include the NCCN Rodger J. Winn award and the ACCC Outstanding Achievement in Clinical Research Award.
Dr. Benson's research is primarily in the areas of gastrointestinal cancer clinical trials, cancer clinical trials, biologic therapies, phase I cancer clinical trials and cancer guideline development. He has authored or co-authored numerous reports, reviews and book chapters focusing on these topics. His research in biologics, cancer therapy and cancer prevention has been awarded funding from a variety of sources including the NIH.
Nicholas J. Petrelli, MD
Bank of America Endowed Medical Director, Helen F. Graham Cancer Center and Research Institute, ChristianaCare
Professor of Surgery, Thomas Jefferson University
Past Chair, Colorectal Committee of the National Surgical Adjuvant Breast and Bowel Project (NSABP)
Dr. Nicholas Petrelli is a Professor of Surgery in the Department of Surgery at Thomas Jefferson University and the Bank of America Endowed Medical Director of the Helen F. Graham Cancer Center and Research Institute at Christiana Care Health Systems, Newark, Delaware.
Dr. Petrelli has been active on numerous advisory panels, including the American Society of Clinical Oncology Expert Panel on Colorectal Cancer Surveillance and the National Cancer Institute Colorectal Cancer Consensus Working Group. He is a member of a number of professional organizations, including the Society of University Surgeons, the American Surgical Association, the American Society of Clinical Oncology, and the Society of Surgical Oncology. He is the past President of the Society of Surgical Oncology and past chair of the Colorectal Committee of the National Surgical Adjuvant Breast and Bowel Project (NSABP).
Dr. Petrelli has authored 335 manuscripts in peer reviewed journals and is the editor of the Surgical Oncology Clinics of North America. He is an associate editor for the Annals of Surgical Oncology and a co-editor of Surgical Oncology.
Dr. Petrelli earned his undergraduate degree from the University of Notre Dame in 1969 and his medical degree from Tulane Medical School in 1973. He completed his general surgery residency in San Francisco in 1978 and post doctoral training in surgical oncology at the Roswell Park Cancer Institute in 1980. He spent the ensuing 21 years at the Roswell Park Cancer Institute during which time he was appointed Chair of the Division of Surgical Oncology and Director of the Surgical Oncology Fellowship Program from 1991 to 2001.
He has been married to his wife Cathy for 38 years and they have two children, Nicole and Gabriella. Nicole has degrees in criminal justice and forensic science and Gabriella in psychology. Dr Petrelli continues to enjoy Delaware beach time with his family and the rich history of the Delaware Valley. He has family in the New York City area, making it convenient for spur of the moment visits. He also has two nephews, Doug and Justin, who keep him young at heart with visits to Midtown Manhattan.
Thomas A. Buchholz, MD, FACR
Senior Vice President and Medical Director, Scripps MD Anderson Cancer Center
Emeritus Professor, Radiation Oncology, The University of Texas MD Anderson Cancer Center
Dr. Thomas A. Buchholz is medical director at Scripps MD Anderson Cancer Center in San Diego. Previously he served as professor of radiation therapy at MD Anderson Cancer Center in Houston where he held the Hubert L. Stringer Distinguished Chair in Oncology in Honor of Sue Gribble Stringer. Dr. Buchholz received his medical degree from Tufts University School of Medicine in Boston and his postdoctoral residency and fellowship training at the University of Washington School of Medicine in Seattle. His major clinical and research interest has been in the field of breast cancer radiation oncology.
Raphael E. Pollock, MD, PhD, FACS
Director, The Ohio State University Comprehensive Cancer Center
Kathleen Wellenreiter Klotz Chair in Cancer Research, Professor and Director, Division of Surgical Oncology, The Ohio State University Wexner Medical Center
Dr. Raphael Pollock, MD, PhD was born in Chicago, IL where he received his primary and secondary school education. Dr. Pollock graduated from Oberlin College in 1972 with a BA in History (high honors). He received his MD degree from St. Louis University, St. Louis, Missouri and then completed residency training in General Surgery at the University of Chicago and Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL. This was followed by a fellowship in Surgical Oncology at the University of Texas MD Anderson Cancer Center, Houston, TX. Upon completion of fellowship training in 1984, Dr. Pollock joined the faculty in the Department of Surgical Oncology at The University of Texas. He completed PhD training at the Graduate School of the Biological Sciences, University of Texas Health Sciences Center / Houston in 1990, and was promoted to Associate Professor the following year. Dr. Pollock became Chairman of the Department of Surgical Oncology in 1993, was promoted to Professor in 1995, and became Head of the Division of Surgery at The University of Texas MD Anderson Cancer Center in 1997. He is currently director at The Ohio State University Comprehensive Cancer Center.
Dr. Pollock has a lifetime professional dedication to patient care and research in soft tissue sarcoma. His clinical practice focuses exclusively on this disease entity, and he has pursued clinical and laboratory research interests in soft tissue sarcoma during the entire time that he has been a member of the faculty of the Department of Surgical Oncology. Currently Dr. Pollock provides leadership for the Sarcoma Research Center at The University of Texas MD Anderson Cancer Center. His laboratory research interests include molecular-oriented tissue- and cell line-based investigations focusing on the role of the p53 tumor suppressor gene in soft tissue sarcoma, modulation of angiogenesis in soft tissue sarcoma, mechanisms of soft tissue sarcoma chemoresistance, as well as the development of novel therapeutics for this disease. Dr. Pollock was the incumbent in the Senator A.M. Aiken, Jr., Distinguished Chair, and held joint appointments in the Department of Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer and the Department of Surgery at The University of Texas Health Sciences Center/ Houston.
Paul A. Bunn, MD, FASCO
Distinguished Professor and James Dudley Endowed Professor of Lung Cancer Research, University of Colorado School of Medicine
Past President and Past CEO, International Association for the Study of Lung Cancer
Amherst College – 1967
Cornell University Medical Center
New York, NY – 1971
In 1984, Dr. Bunn was recruited to the University of Colorado Health Sciences Center as a Professor of Medicine in Medical Oncology and Head of the Division of Medical Oncology. In 1986, Dr. Bunn became the Director of the University of Colorado Comprehensive Cancer Center. Dr. Bunn has been President of ASCO, IASLC, and AACI, chairman of the FDA Oncology Drug Advisory Committee, and is currently the Executive Director of the IASLC.
Dr. Bunn's research interests focus on novel therapies for lung cancer. He has published more than 300 articles in peer-reviewed journals, 122 reviews and 90 book chapters on lung cancer. Dr. Bunn's studies have set standards for the treatment of lung cancer, have identified issues of natural history and have identified biomarkers of prognosis and therapy selection. Dr. Bunn is the principal investigator on numerous national and local therapeutic trials and is also the principal investigator for the SPORE grant in lung cancer that is designed to conduct translational research.
Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA, Jr. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18(4), 752-60, 2007.
Frederick B., Helfrich B., Coldren C.,. Zheng D., Chan D., Bunn P.A., Jr, Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small-cell lung cancer. Mol Cancer Ther 6:(6), 2007.
University of Colorado Cancer Center Support Grant: NIH/NCI 4/4/97-1/31/11. $2,832,858 - 45% effort. The major goals are to contribute, through a coordinated research, clinical treatment, control and education effort to the eventual elimination of cancer as a human health problem and provide the citizens of the State of Colorado and the Rocky Mountain Region with state-of-the-art cancer therapy, research, control and education programs.
SPORE In Lung Cancer: NIH/NCI 09/30/1992 to 04/30/2013. $1,600,999 - 25% effort combined
The major goal of the overall project is to establish a Specialized Program in Research Excellence (SPORE) in Lung Cancer to expand our understanding of the biology of lung cancer, to find new methods of diagnosis, prevention and treatment and to serve as a regional, national and international resource for the study of lung cancer.
Richard B. Reiling, MD
Dr. Richard Reiling is a native of Dayton, Ohio and received his undergraduate education at the University of Dayton. In the interim between undergraduate studies and medical school, he was a high school teacher, the beginning of a life-long avocation for teaching. After graduating from Harvard Medical School he completed training in surgery at Harvard and an oncology Fellowship at the Lahey Clinic.. He served in the USAF during the Vietnam conflict era. Dr. Reiling entered private practice in his hometown at the same time that a new medical school was being formed in Dayton. He became a charter faculty member at Wright State University School of Medicine and remains on that faculty throughout his career. Currently, Richard is a Clinical Professor of Surgery at Wright State.
Dr Reiling's personal interest has always been in the care of patients with cancer, especially those with breast cancer. He was instrumental in developing a cancer program at his main hospital, Kettering Medical Center, named after the inventor Charles F. Kettering and located on the lawns of the former Kettering estate. The hospital was shortly thereafter recognized by US News and World Report as one of the nation's top 50 hospitals for cancer care. During this time he continued a very active practice as well as a busy teaching schedule.
In the summer of 2000, he was recruited by Ohio Health's flagship hospitals in Columbus, Ohio as the VP for Cancer Services. During the next several years, Dr. Reiling provided the support and leadership to bring that institution's cancer program to a high level of recognition in a community that already had a major cancer hospital as part of Ohio State University.
He found an offer to a similar position as the Medical Director of the Presbyterian Cancer Center too good to not accept. The position at Presbyterian and the beauty of the city was enough for the Reilings to give up their Ohio roots and move to the Carolinas.
Dr. Reiling has worked diligently to develop programs that improve the care of patients with cancer. In addition to breast cancer, he is especially active in lung cancer. It is in this situation that he has a very strong interest in the prevention of lung cancer and other respiratory diseases related to cigarette smoke. He has served with SmokeFree Mecklenburg for several years and often speaks and writes about the hazards of second-hand smoke.
Dr. Reiling has served on many professional society boards and committees, including the President of the Ohio Chapter of the American College of Surgeons and a Governor of the American College of Surgeons. Currently, he is the Second VP-Elect of the American College of Surgeons. In addition, he has served on many community and church organizations including the United Way, and the Dayton Opera Association. In his spare time, he was able to be a Boy Scout Master for a troop in Kettering Ohio, and proudly lists many young men who became Eagle Scouts during his tenure. Currently he serves on the Mecklenburg Council of the Boys Scouts of America, along with other civic boards. He is a member of the Charlotte Rotary Club.
Dr. Reiling is married to his childhood sweetheart, Liz, and celebrated their 44th anniversary this June. The Reilings have two grown children, Maureen DeBlois, a senior hospital executive in Atlanta, and Richard B. Reiling Jr., an attorney in Boston. The Reiling's have 3 grandchildren. Richard enjoys golf, skiing, and just being involved.
Michael A. Caligiuri, MD
President and Physician-in-Chief, City of Hope National Medical Center
Past President, American Association for Cancer Research
Michael A. Caligiuri, MD, is director of The Ohio State University Comprehensive Cancer Center, chief executive officer of Ohio State's James Cancer Hospital and Solove Research Institute, and holder of the John L. Marakas Nationwide Insurance Enterprise Foundation Chair in Cancer Research. He also is a professor in the Department of Internal Medicine and the Department of Molecular Virology, Immunology and Medical Genetics in Ohio State's College of Medicine. Dr. Caligiuri's laboratory has evolved to investigate:
- Development and normal role of the body's large granular lymphocytes called natural killer cells so as to exploit their properties to develop effective therapies against cancer and immune deficiency;
- Why organ transplant patients with iatrogenic immune deficiency are highly susceptible to developing lymphoma associated with the Epstein-Barr virus, and to develop a preventive strategy for this disorder. His lab uses a SCID-human mouse model to explore therapies for treating this and other types of lymphoma;
- The molecular basis for the development of acute leukemia. His lab has mouse models of leukemia as well as the world's largest bank of human leukemia cells to study the pathogenesis of acute leukemia, the prognostic significance of molecular defects in acute leukemia, and novel therapies for acute leukemia.
Since 1990, more than 100 students have trained in the Caligiuri laboratory and have received numerous awards for their research. Dr. Caligiuri has designed and conducted many clinical studies for leukemia and lymphoma patients and has more than 400 original publications, abstracts and review articles on immunology or leukemia.
He also is an elected member of the American Society for Clinical Investigation and the Association of American Physicians, and he is an elected Fellow in the American Association for the Advancement of Science. In 2007, he was elected as vice president and president-elect of the Association for American Cancer Institutes (AACI), and he served as AACI president through 2011. He chairs the AACR Publications Committee and is a past editor of the journal Blood. Dr. Caligiuri has served on numerous national and international committees, including the National Cancer Institute (NCI) Board of Scientific Advisors; he either chairs or is a member of 12 cancer center advisory boards across the country. In 2010, Dr. Caligiuri was one of four individuals in the country to receive a MERIT award from the National Cancer Institute for his work on immunity and cancer.
Dr. Caligiuri earned his medical degree from Stanford University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women's Hospital at Harvard Medical School in Boston, then completed a fellowship in medical oncology, bone marrow transplantation and immunology at the Dana-Farber Cancer Institute at Harvard Medical School. He next spent seven years at Roswell Park Cancer Institute as an assistant, associate and full professor before moving to The Ohio State University in 1997.
William S. Rosenberg, MD
Neurosurgeon and Founder, Center for the Relief of Pain, Kansas City, MO.
President Emeritus and Founder, Cancer Pain Research Consortium
A California native, Dr. William S. Rosenberg attended Harvard Medical School in Boston, graduating in 1987. He completed his neurosurgical residency at Massachusetts General Hospital, also located in Boston, in 1993. He is a Fellow of the American Association of Neurological Surgery and a Diplomate of the American Board of Neurological Surgery.
Dr. Rosenberg began his career with the Mayfield Clinic in Cincinnati (1994 to 1998), where he was the Director of Neurotrauma and Neurocritical Care at the University of Cincinnati and specialized in complex spinal surgery. He was then recruited to co-direct the Neurospinal Disorders Program in the Department of Neurosurgery, University of California, San Francisco, from 1998 to 2002, where he co-founded the Spinal Biomechanics Laboratory at the University of California, Berkeley. Dr. Rosenberg left academic neurosurgery in 2002, joining Midwest Neurosurgery Associates in Kansas City, Mo., out of a desire for greater focus on patient care and the ability to spend more time with family.
In Kansas City, Dr. Rosenberg continued to pursue interests in complex spinal surgery. He brought CyberKnife Radiosurgery to the Kansas City area and served as medical director for the Menorah CyberKnife Center for its first six years. In addition, he expanded his area of expertise to include the treatment of chronic and cancer-related pain, founding and directing the Center for the Relief of Pain at Research Medical Center, where patient-centered, diagnosis-based pain care is emphasized. Perceiving an unmet need in cancer pain care, Dr. Rosenberg founded and is president emeritus of the Cancer Pain Research Consortium, a multidisciplinary group of experts from across North America dedicated to the generation and promotion of patient-centered, evidence-based care for cancer-related pain and suffering. Dr. Rosenberg is actively involved in treating patients with such modalities as neuromodulation, intrathecal pharmacotherapy, peripheral nerve, spinal cord and deep brain stimulation. He is also very active in training other health care providers, curriculum development and lecturing, as well as designing and supervising clinical trials.
Dr. Rosenberg is a member of the American Association of Neurological Surgeons, Congress of Neurological Surgeons, North American Spine Society, American Academy of Pain Medicine, International Neuromodulation Society, North American Neuromodulation Society, AANS/CNS Joint Section on Pain, American Society of Stereotactic and Functional Neurosurgery, American Society for Clinical Oncology, Missouri State Medical Society, Metropolitan Medical Society, Kansas City Neurology/Neurosurgery Society and the Greater Kansas City Pain Society. He provides editorial support for Neuromodulation, the official journal of the North American Neuromodulation Society where he also serves on the Website and Education Committees. He is a member of the Scientific Review and Guidelines Committee for the American Academy of Pain Medicine and is an Executive Committee member of the AANS/CNS Joint Section on Pain.
Kaisorn L. Chaichana, MD
Associate Professor of Neurosurgery, Director of Skull Base and Minimally Invasive Cranial Surgery, Director of Brain Tumor Surgery, Mayo Clinic, Jacksonville, FL
Dr. Kaisorn L. Chaichana is an associate professor of neurosurgery and director of skull base and minimally invasive cranial surgery at Mayo Clinic, Jacksonville FL. Previously he was assistant professor of neurosurgery, oncology and otolaryngology and director of brain tumor surgery at Johns Hopkins University School of Medicine. Dr. Chaichana is an active researcher in clinical outcomes and brain tumor stem cell research. He has published over 100 peer-revised papers in various prestigious journals.
Howard G. Rosenthal, MD
Associate Professor of Orthopedic Surgery, The University of Kansas Health System, Sarcoma Center
With more than 25 years of experience treating patients with tumors of the bone and soft tissues, Dr. Rosenthal is one of the foremost authorities in sarcoma surgery and treatment, having performed more than 4,500 limb salvage surgeries for musculoskeletal tumors since 1990. He is a fellow of the American College of Orthopaedic Surgeons and the American College of Surgeons. He has published numerous works and presented papers and lectures on limb preservation and sarcoma treatment. He serves on various committees of the Musculoskeletal Tumor Society, the International Society of Limb Salvage Surgeons, and the Connective Tissue Oncology Society.
Armando E. Giuliano, MD, FACS, FRCSEd
Professor of Surgery, Executive Vice Chair of Surgery, Associate Director, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center
Armando E. Giuliano, M.D., is Executive Vice Chair of Surgery, Chief of Surgical Oncology, Professor of Surgery, and the Linda and Jim Lippman Chair in Surgical Oncology at Cedars-Sinai Medical Center, and he has been a clinician-researcher his entire career. He has served as chairman of the Breast Organ Site Committee of the American College of Surgeons Oncology Group Breast Research Committee and was author and principal investigator for the sentinel node Z0010 and Z0011 studies which significantly changed the standard of care for patients with early breast cancer. He was the first to successfully perform a sentinel node biopsy for breast cancer and has been a pioneer in the field. The main focus of his clinical research continues to be management of early breast cancer and quality of life of breast cancer patients.
Currently Dr. Giuliano is President of the Society of Surgical Oncology and also serves on the American College of Surgeons Board of Governors. He is very active in teaching fellows and residents and has earned numerous teaching awards. In 2011, he was one of only three physicians to be awarded Castle Connolly's national Clinical Excellence Award. He also received the Glenn-Robbins Award from Memorial Sloan-Kettering Cancer Center and the Susan G. Komen for the Cure® Brinker Award for Scientific Distinction in Clinical Research. Dr. Giuliano is a frequent speaker at national and international conferences and has been a visiting professor in the U.S., Europe and Asia. He is the author of more than 500 scientific articles and book chapters and has edited a textbook. His work on lymph node metastasis has changed the management of breast cancer worldwide.
Peter T. Scardino, MD
Chair of Surgery, Chief of Urologic Oncology, Head of the Prostate Cancer Research Program, Memorial Sloan Kettering Cancer Center
Professor of Urology, Weill Medical College of Cornell University
Yale University, New Haven, CT
Duke University School of Medicine, Durham, NC
PROFESSIONAL POSITIONS AND EMPLOYMENT
Post-doctoral training (include residency/fellowships)
Surgical Resident
Massachusetts General Hospital, Boston, Massachusetts
Clinical Associate, Surgery Branch
National Cancer Institute, National Institutes of Health, Bethesda, Maryland (fellowship in urologic oncology)
Urology Resident
UCLA, Los Angeles, California
Executive Development Program
School of Business Administration, University of Houston, Houston, Texas
Chiefs of Service Program
Harvard University School of Public Health, Boston, Massachusetts
Academic positions (teaching and research)
Instructor in Urology
Assistant Professor of Urology
Baylor College of Medicine, Houston, Texas
Associate Professor of Urology
Professor of Urology
Russell and Mary Hugh Scott Professor and Chairman
Scott Department of Urology, Baylor College of Medicine, Houston, Texas
Weill Medical College of Cornell University, New York
Memorial Sloan-Kettering Cancer Center (MSKCC), New York
Head, Prostate Cancer Program
MSKCC
Chief of the Urology Service
Murray F. Brennan Chair in Surgery, Department of Surgery, MSKCC
Department of Urology and Alfred P. Sloan Chair, MSKCC
Sloan-Kettering Institute for Cancer Research, New York
Florence and Theodore Baumritter/Enid Ancell Chair of Urologic Oncology
Department of Urology, College of Medicine, State University of New York Downstate Medical Center at Brooklyn, Brooklyn, New York
Acting Chief
Urology Service, Department of Surgery, MSKCC
David H. Koch Chair
Department of Surgery, MSKCC
Hospital positions (e.g., attending physician)
Senior Attending, Urology, and Chief of the Urology Service (1989-1998)
The Methodist Hospital, Houston, Texas
Active Staff, Urology, and Chief of the Urology Service (1989-1998)
Harris County Hospital District (Ben Taub General Hospital), Houston, Texas
Senior Attending Urologist
St. Luke's Episcopal Hospital, Houston, Texas
Attending Surgeon
Memorial Hospital, New York, New York
Attending Urologist
New York Presbyterian Hospital-Cornell Medical Center, New York, New York
LICENSURE, BOARD CERTIFICATION, MALPRACTICE
National Board of Medical Examiners, 07/92
American Board of Urology, 1981
Do you have Malpractice Insurance? Yes
Name of Provider: MSK Insurance Ltd.
Premiums Paid by: Memorial Sloan-Kettering Cancer Center
PROFESSIONAL MEMBERSHIPS (medical and scientific societies)
Member/Chair Section 6
Institute of Medicine, National Academy of Sciences (IOM)
American Surgical Association (ASA)
Clinical Society of Genitourinary Surgeons (CSGUS)
American Association of Genitourinary Surgeons (AAGUS)
American Urological Association (AUA)
Society of University Surgeons (SUS)
American College of Surgeons (FACS)
American Society of Clinical Oncology (ASCO)
American Association for Cancer Research (AACR)
Society of Urologic Oncology (SUO)
The Society of Surgical Oncology, Inc. (SSO)
Canadian Urological Association
The Urological Society of Australasia
Société Internationale d'Urologie (SIU)
Urological Investigators Forum (UIF)
Western Urological Forum (WUFER)
Society for Basic Urologic Research (SBUR)
Society of University Urologists (SUU)
The New York Academy of Sciences (NYAS)
The New York Academy of Medicine (NYAM)
South CentralSection, American Urological Association (SCSAUA)
South Eastern Section, American Urological Association (SESAUA)
New York Section, American Urological Association (NYSAUA)
New York County Medical Society
New York Clinical Society
New York Medical and Surgical Society
New York State Urological Society, Inc. (NYSUS)
First Prize, Scientific Exhibit, American Urological Association
Outstanding Faculty Member of the Year (one of six), Baylor College of Medicine
George Slotkin Honorary Lecturer, New England and Northeastern Sections, AUA, Boston
Leo Roon Visiting Professor, Harvard Medical School, Boston
Gold Cystoscope Award, AUA (awarded to the individual who has contributed the most to urology within 10 years of his residency)
Ballenger Memorial Lecturer and Appointed Honorary Member, Southeastern Section, AUA
Named one of "The 400 Best Doctors in America" by Good Housekeeping magazine
Director, Matsunaga-Conte Prostate Center Research Center, a designation by the National Cancer Institute of the Baylor College of Medicine SPORE (Specialized Program of Research Excellence), the first SPORE in prostate cancer awarded by the NCI
Royal College of Surgeons Lecturer, Dublin, Ireland
Listed in The Best Doctors in America, edited by Steven Naifeh and Gregory White Smith, Aiken: Woodward/White, Inc., p. 519
Eugene Fuller Triennial Prostate Award of the AUA
George Slothin Lecturer, Northeast Section, American Urological Association
Named one of "The Best Medical Specialists" by Town & Country magazine
Elected to the Institute of Medicine, National Academy of Sciences
AUA Lecturer, European Association of Urology Biennial Meeting, Paris, France
American Foundation for Urologic Disease Presidential Award
Named one of "The Best Doctors in America" by American Health magazine
British Journal of Urology Guest Lecturer, British Association of Urological Surgeons Annual Meeting
Royal College Lecturer, Canadian Urological Association
Kaneharu Suzuki Award, Suzuki Foundation for Urological Medicine, Japan
Letter of Commendation from Richard D. Klausner, M.D. (Director, National Cancer Institute, National Institutes of Health) for work done on behalf of the National Cancer Institute's Prostate Cancer Progress Review Group, Bethesda, Maryland
Gordon Wilson Lecturer, American Clinical and Climatological Association
William P. Burpeau Award, West Orange, New Jersey
Distinguished Alumnus Award, Duke University Medical Center, Durham, North Carolina
Named one of "Best Doctors In New York City" by New Yorkmagazine
Featured in TheNew York Times,The Wall Street Journal, USA Today, Washington Post, andThe New Yorker,People, Men's Health, Forbes,andIn Touch magazines. TV and radio appearances: ABC World News Tonight, NBC Nightly News, NBC Today Show, WNBC Live At Five, WABC - Eyewitness News, WCBS Radio, Health Show - National Public Radioand CBS Network Radio
Keynote speaker, American Association for Cancer Research, New Discoveries in Prostate Cancer
McPeak Lecturer, Society of the Memorial Sloan-Kettering Alumni
Principal Investigator, SPORE in Prostate Cancer, Memorial Sloan-Kettering Cancer Center
AUA Lecturer, Societe Internationale d'Urologie Meeting, Stockholm, Sweden
Presidential Lecturer, Southeastern Section, American Urological Association
Folke Edsmyr Memorial Lecturer and Award, Karolinska Institute, Stockholm, Sweden
Society of Urologic Oncology Medal
Henry Lichtwardt Lecturer, William Beaumont Hospital Graduation, Royal Oak, MI
XXXI Sir Peter Freyer Memorial Lecture, Galway, Ireland
Dr. G.M. Phadke Memorial Oration, Urological Society of India, Patna, India
Whitmore Lecturer, Society of Urologic Oncology
Named one of "The Best Doctors in America," America's Top Doctors, Castle Connolly Medical Ltd
Named one of "The Best Doctors in New York," New York Magazine
Named one of "New York Super Doctors" by New York Times Magazine
Distinguished Contribution Award, American Urological Association
Barringer Medal, American Association of Genitourinary Surgeons
INSTITUTIONAL/HOSPITAL AFFILIATION
Primary Hospital Affiliation
Memorial Hospital for Cancer and Allied Diseases
Other Hospital Affiliations
Other Institutional Affiliations
Name of Current Employer(s):
Employment Status (choose one):
CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT EFFORT
Postgraduate Education Courses Directed
Innovations in Urologic Practice, Postgraduate Course, Baylor College of Medicine
1985, 1987, 1996-1997
Ultrasonography in Urology, Postgraduate Education Course, American Urological Association
Transrectal Ultrasonography for Prostate Cancer, Annual Postgraduate Education Course, Baylor College of Medicine
Urologic Surgery, Post Graduate Course, American College of Surgeons
Prostate Cancer, Annual Postgraduate Education Course, American Urological Association
1990-1997, 1999-2004
New Surgical Approaches in Prostate Cancer, New York Section of the American Urological Association, Barcelona, Spain
Open and Laparoscopic Radical Prostatectomy, MSKCC, New York
Treatment of High-Risk Prostate Cancer, Annual Postgraduate Education Course, American Urological Association
Outpatient office hours, 2 half days per week
Operating room, 2 days per week
Ward rounds, 5 days per week
Institutional Review Board for Human Research
Chair, Admissions Committee
Director, Residency Training Program, Scott Department of Urology
Education 2001 Task Force
Executive Faculty Committee
Faculty Appointments and Promotions Committee
Internal Advisory Committee on Center for Molecular Medicine
Search Committee, Director of Center for Gene Therapy
Baylor MedCare Executive Committee and Board of Directors
Academic Programs Committee
Committee on Review (appointments and promotions), Weill Medical College of Cornell University
Vice Chairman, Biomedical Ethics Committee, The Methodist Hospital
Surgical Executive Committee
Co-Chair, Genitourinary Cancer, Disease Management Team
Compliance Committee
Search Committee, Chief of Plastic Surgery
Memorial Hospital Committee on Credentials, Appointments and Promotions (MHCCAP)
Committee on Appointments and Promotions (COAP)
Chair, Search Committee for Chair of Pathology
Discovery and validation of tissue markers of progression in prostate cancer
Development of new models of progression and decision-analysis using medical informatics
Longitudinal assessment of health related quality of life in men with localized prostate cancer
Optimizing surgical techniques for prostate cancer
Translational research in prostate cancer
Current Percent Effort (%)
Does the activity involve WMC students or researchers?
Does the activity involve MSK trainees or researchers?
Teaching/Mentoring
U01 CA84999-05 Molecular Classification of Prostate Cancer
10/1/1999-03/31/2006
Principal Investigator: WL Gerald
Role: Co-Investigator
Major goals: to define molecular profiles representative of androgen-independent prostate carcinoma by comprehensive, microarray-based gene expression analysis and comparison of androgen-dependent and —independent tumors, to develop robust molecular histopathologic methods to identify and quantitate androgen-dependent and —independent tumor cell subclones within primary human prostate carcinomas, and to analyze the relationship between molecular classification and clinical course of disease.
P50-CA 92629-06 SPORE in Prostate Cancer
NIH/NCI
Principal Investigator: PT Scardino
The major goals of this project are to continue the development of novel systemic therapy for prostate cancer. The development of better prognostic models of lethal variants of early stage prostate cancer and the characterization of important molecular pathways that lead to progression and metastases were designed to support our therapeutic objective by elucidation of specific targets within prostate cancer cells appropriate for mechanism-based therapy. Our central hypothesis has been that the molecular determinants of prostate cancer development and progression vary as the disease evolves.
Prostate Cancer Foundation (Award)
Prostate Cancer Research Program
7/1/03-12/31/06
% Effort: N/A
Major goal: To identify new tissue markers of progression and metastasis of human prostate cancer, analyze tissue specimens with a systems pathology, high throughput approach and characterize the long-term natural history of clinical localized prostate cancer
T32 CA082088-07 Urology Oncology Research Training Grant (first awarded in 1999)
15% effort
Major goal: to produce for the nation a larger cadre of superbly trained clinical scientists to become leaders in academic urologic oncology and who will be highly qualified to promote the revolution of medical care made possible by the developments in modern biomedical science.
William J. Gradishar, MD, FACP, FASCO
Betsy Bramsen Professor of Breast Oncology & Professor of Medicine
Chief, Division of Hematology/Oncology, Department of Medicine
Deputy Director, Clinical Network
Director, Maggie Daley Center for Women's Cancer Care
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Dr. William J. Gradishar is the Chief of, as well as Betsy Bramsen Professor of Breast Oncology and Professor of Medicine in, the Division of Hematology and Medical Oncology, Department of Medicine, at the Feinberg School of Medicine at Northwestern University in Chicago, Illinois, and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He serves as Director of the Maggie Daley Center for Women's Cancer Care. Additionally, he is Deputy Cancer Center Director (Clinical Network) and Deputy Chief of the Division of Hematology and Medical Oncology and System Head for Medical Oncology across Northwestern Medicine. He has been Chair of the Annual Lynn Sage Breast Cancer Symposium since its inception 18 years ago. He served as Program Director of the Hematology Oncology Fellowship Training Program at Northwestern for 20 years. His research focuses on the development of novel therapeutics for the treatment of breast cancer.
A Fellow of the American College of Physicians and the American Society of Clinical Oncology, Dr. Gradishar is also a member of the American Association for Cancer Research, the American Federation for Clinical Research, and the Association of Subspecialty Professors. He is past Chair of the Oncology Training Program Committee, Chair of the Communications Committee, Chair of the Professional Development Committee and Chair of the Nominating Committee of the American Society of Clinical Oncology (ASCO) as well as a member of ASCO's Scientific Program Committee. He is a member of the Breast Cancer Core Committee of the Eastern Cooperative Oncology Group, past member of the Committee on Cancer of the American College of Surgeons and current Chair of the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines Panel, and the NCCN Breast Cancer Prevention Panel. In addition, he serves as a consultant to the Oncology Drug Advisory Committee of the FDA. He is Chair of the Breast Cancer Working Group/Moonshot 2020. He has served on numerous study sections including: NIH, NCI, ACS, Komen, Alberta Cancer Board, National Cancer Institute of France, and Czech Cancer Institute. He is a member of the editorial board for numerous journals, including Journal of Clinical Oncology, Oncology, Clinical Breast Cancer, European Journal of Clinical and Medical Oncology and Clinical Cancer Research. He is the founding Editor-in Chief of NEJM Journal Watch Hematology/Oncology. He is Co-Editor of The Breast, the definitive 2-volume textbook on benign and malignant breast disorders. He has published in the area of breast cancer therapeutics, with a focus on new endocrine therapy, chemotherapy and biologic agents. Dr. Gradishar holds the Betsy Bramsen Endowed Chair of Breast Oncology at Northwestern University.
Dr. Gradishar received his medical degree form the University of Illinois Abraham School Of Medicine in Chicago. He completed a residency and chief residency in internal medicine at Michael Reese Hospital and Medical Center in Chicago and a clinical research fellowship in medical oncology at the University of Chicago.
George W. Sledge Jr., MD
Professor of Medicine, Chief, Division of Oncology, Stanford University
George W. Sledge Jr., MD, is professor and chief of medical oncology at Stanford University Medical Center and most recently served as co-director of the breast cancer program at the Indiana University Cancer Center. He specializes in the study and treatment of breast cancer and directed the first large, nationwide study on the use of paclitaxel to treat advanced breast cancer. He has published more than 280 articles in medical journals about breast cancer and chaired several nationwide clinical trials involving new breast cancer treatments. His work spans both laboratory and clinic.
Dr. Sledge serves as editor-in-chief of the journal Clinical Breast Cancer, and is past president of the American Society of Clinical Oncology. He served as chairman of the Breast Committee of the Eastern Cooperative Oncology Group from 2002 to 2009, where he played an important role in the development of several nationwide clinical trials. He has also served as chair of ASCO's Education Committee, as a member of the Department of Defense Breast Cancer Research Program's Integration Panel, as a member of the Food and Drug Administration's Oncology Drug Advisory Committee, and currently as a member of the External Advisory Committee for The Cancer Genome Atlas project.
Dr. Sledge was awarded the Hope Funds for Cancer Research 2013 Award of "Excellence for Medicine." He was also the recipient of the 2006 Komen Foundation Brinker Award for Scientific Distinction, the 2007 Breast Cancer Research Foundation's Jill Rose Award and the 2010 William L. McGuire Award from the San Antonio Breast Cancer Symposium.
Frederick L. Greene, MD, FACS
Medical Director, Cancer Data Services, Levine Cancer Institute
Past Chair, Commission on Cancer & American Joint Committee on Cancer
Frederick L. Greene, MD, FACS, received his medical school training at the University of Virginia where he was elected to membership into AOA. He completed a residency in surgery at Yale University School of Medicine. Dr. Greene was also an American Cancer Society Clinical Research Fellow at Yale. He was on active duty with the United States Navy and was surgeon on the USS Nimitz. He is currently the Chairman of the Department of General Surgery at Carolinas Medical Center in Charlotte, North Carolina, Director of the Surgical Residency Program at that institution and Clinical Professor of Surgery at the University of North Carolina School of Medicine.
Dr. Greene is an active clinician in the area of surgical oncology and has been involved in organizational work pertaining to cancer for a number of years. Dr. Greene is a Fellow of the American College of Surgeons and has served on the Board of Governors of that organization. Dr. Greene serves on the Commission on Cancer of the American College of Surgeons and served as the Chair of the Commission from 2004-2008. He has represented the American College of Surgeons on the American Joint Committee on Cancer (AJCC) and served as Chair of the AJCC from 2000-2006. Dr. Greene is the Editor of the 6th Edition of the AJCC Cancer Staging Manual.
Dr. Greene belongs to numerous surgical organizations including the Society of Surgical Oncology, the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), the Southern Surgical Association and the American Surgical Association. Dr. Greene was a founding member of SAGES and served as its president in 1992-93.
Dr. Greene's publications have included approximately 160 papers, 30 book chapters and two textbooks relating to cancer surgery and, specifically, the use of laparoscopic surgery in the management of cancer patients. Dr. Greene serves as the Associate Editor of the Annals of Surgical Oncology and on numerous editorial boards including Surgical Endoscopy, Journal of Surgical Education, Journal of Surgical Oncology, World Journal of Surgery , American Surgeon, Journal of Clinical Oncology, Surgical Endoscopy, Laparoscopy and Percutaneous Techniques and is Editor of General Surgery News.
Donald L. Trump, MD, FACP
Founding CEO, Inova Schar Cancer Institute (retired)
Professor of Medicine, University of Virginia (retired)
Dr. Donald L. Trump is a medical oncologist specializing in treating genitourinary cancers with a particular focus on prostate cancer. Dr. Trump is a Diplomate of the American Board of Internal Medicine, with Subspecialty Boards in Medical Oncology, and a Fellow of both the American Society of Clinical Oncology and the American College of Physicians.
Dr. Trump earned his medical degree from The Johns Hopkins University School of Medicine in 1970. From 1970 to 1975, he completed an internship and residency training in Medicine and a fellowship in Oncology and served as Chief Resident in Internal Medicine at The Johns Hopkins Hospital.
Dr. Trump is past Secretary/Treasurer of the American Society of Clinical Oncology and is a member of many professional and scientific societies. He is a reviewer and/or member of the editorial board of prestigious journals, such as the New England Journal of Medicine, Journal of National Cancer Institute, Cancer, Journal of Urologic Oncology, Clinical Cancer Research, Patient Resource Cancer Guide, Cure, Oncology, American Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Cancer Research, and Journal of Clinical Oncology. Dr. Trump has authored or co-authored more than 300 journal publications, book chapters and abstracts.
Mario E. Lacouture, MD
Director, Oncodermatology Program, Professor of Dermatology, Memorial Sloan Kettering Cancer Center
Dr. Lacouture is a board-certified dermatologist with special interest in dermatologic conditions that result from cancer treatments. His clinical career has been focused on the recognition and management of side effects affecting the skin, hair and nails of cancer patients and survivors, which can occur as a consequence of chemotherapy, radiation therapy and therapeutic transplants.
To ensure that dermatologic side effects do not affect quality of life and the consistent administration of anticancer therapies, Dr. Lacouture has founded the SERIES (Skin and Eye Reactions to Inhibitors of EGFR and kinases) Clinic, an interdisciplinary effort comprising patient care, education and research. This unique clinical program provides pretreatment counseling and preventive efforts to minimize the development of side effects as well as rapid attention to those patients who develop them. Close communication with treating oncologists ensures that interventions against side effects do not affect the effectiveness of cancer treatments to ensure the best dermatology-related quality of life and benefit from anticancer treatments.
Dr. Lacouture's research focuses on major components of dermatologic side effects: the accurate description and severity grading; the effects on quality of life; the identification of factors that place individuals at higher risk; and the development of treatments. A basic tenet of this research is in exploring new skin treatments that do not affect the effectiveness of anticancer drugs. For example, topical medicines in the face or regional cooling of hands or feet are used to prevent or treat drug-induced side effects in these areas. Currently, dermatologic effects of cancer therapies in long-term cancer survivors are being investigated, the first step towards ensuring long-term skin health after cancer therapies.
In addition to his role in the treatment of dermatologic conditions in cancer patients and survivors, he is co-chair of the Skin Toxicity Study Group of the Multinational Association of Supportive Care in Cancer, an international organization devoted to the understanding of side effects in cancer patients.
Terry T. Tsue, MD, FACS
Vice President of Physician Services, The University of Kansas Health System
Vice President and Physician-in-Chief, The University of Kansas Cancer Center
Interim Chair, Department of Radiation Oncology, Douglas A. Girod, MD, Endowed Professor of Head and Neck Surgical Oncology, Department of Otolaryngology - Head and Neck Surgery, The University of Kansas School of Medicine
Dr. Terry T. Tsue is currently vice president of physician services of The University of Kansas Health System and the vice president and physician-in-chief of The University of Kansas Cancer Center. He specializes in head and neck cancer, thyroid cancer and skull base surgery. He is also the senior examiner for the American Board of Otolaryngology in Houston and member of the ACGME Otolaryngology Residency Review Committee. He serves as chair of the RRC Milestones Committee.
Marty A. Makary, MD, MPH, FACS
Chief, Minimally-Invasive Surgical Oncology, Johns Hopkins Hospital
Professor of Surgery and Health Policy, Johns Hopkins University School of Medicine
Dr. Makary specializes in minimally-invasive cancer surgery and is professor of surgery and health policy at Johns Hopkins University. Dr. Makary is an active researcher, focusing on the delivery of health care and public health implications of new medical interventions. He is a frequent medical commentator for CNN and Fox News, and speaks nationally on the subjects of healthcare quality, health policy and cancer prevention.
Dr. Makary led The United Nations World Health Organization (W.H.O.) technical work group to develop standardized health metrics to compare surgical outcomes across countries. From his overseas experiences, Dr. Makary founded The Lotus Global Health Foundation®, a non-profit organization which supports humanitarian medical efforts in developing countries.
Dr. Makary is the recipient of numerous research and teaching awards, including the Research Award of the Washington Academy of Surgery and the Best Teacher Award for Georgetown Medical School.
He is the author of "General Surgery Review", a textbook of surgery, and over 100 scientific publications. His research expertise includes high-risk populations, environmental health, and risk management in medicine. He is internationally recognized for outcomes research and his work has been published in The New England Journal of Medicine and The New York Times.
In 2007, he was named the Mark Ravitch Endowed Chair in Gastrointestinal Surgery, becoming the youngest surgeon at Johns Hopkins to receive an endowed chair.
Dr. Makary holds degrees from Harvard University, Thomas Jefferson University, and Bucknell University. He completed surgical training at Johns Hopkins University and Georgetown University.
Global Medical Advisory Board Members:
Antonio Carlos Buzaid, MD (Brazil)
Chairman, Oncology Center of the Hospital São José de Beneficencia Portuguesa de São Paulo, Brazil
Dr. Buzaid is an internist and medical oncologist in São Paulo, Brazil. He has served as the general director of the Oncology Center Hospital Sirio- Libanes in São Paulo as well as the medical director of the Melanoma and Skin Center at the University of Texas M. D. Anderson Cancer Center. He has also served as the medical director of the Melanoma Unit and co-director of the Lung Cancer Unit at Yale Comprehensive Cancer Center in New Haven, Conn. Dr. Buzaid is co-editor of the Manual de Oncologia do Brasil (10th edition), which has been translated into Spanish and English with more than 45,000 copies sold.
Gabriel N. Hortobagyi, MD, FACP (U.S.)
Professor of Medicine, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center
Universidad Nat'l of Columbia, MD Degree in Medicine, 1970.
St. Luke's Hospital, Cleveland, OH, Resident Internal Medicine, 1971-74
U.T. MD Anderson Hospital, Houston, TX, Fellow Medical Oncology, 1976A. Positions and Honors Positions and Employment
1976-1977 Faculty Associate, Medical Breast Service, UTMDACC
1977-1980 Assistant Professor of Medicine, UTMDACC
1980-1985 Associate Professor of Medicine, UTMDACC
1980-1985 Director, Fellowship Program, Dept. Medical Oncology, UTMDACC
1984-1992 Chief, Breast Medical Oncology Service, UTMDACC
1985-Present Professor of Medicine, UTMDACC
1992-Present Chairman, Breast Medical Oncology, UTMDACC
1992-Present Director, Breast Cancer Research Program, UTMDACC
1998-Present Nellie B. Connally Chair in Breast Cancer, UTMDACC
Other Experience and Professional Memberships
1975 Diplomat, American Board of Internal Medicine
1977 Diplomat, American Board of Internal Medicine (Medical Oncology)
1993 - Present Corresponding Member - National Academy of Medicine, Argentina
1994 - Present Corresponding Member - National Academy of Medicine, Mexico
1995 Cino del Duca Award (Paris-France)
1997 Brinker International Award (Susan G. Komen Breast Cancer Foundation)
1999 Vermeille Medal of the City of Paris, France
2001 Chevalier de la Legion d'Honneur, Paris, France
2003 Horizon Scientific Achievement Award in Breast Cancer
2003 Glenn Robbins Award, New York Cancer Society
2004 Jeffrey A. Gottlieb Memorial Award
2004 - Present External Member - National Academy of Sciences, Hungary
2005 Laurea Honoris Causa – University of Modena and Reggio Emilia, Italy
2006 Pathfinder Award – American Society of Breast Disease
2006 - 2007 President, American Society of Clinical Oncology
2007 – Present Chair, Southwest Oncology Group Breast Committee
B. Selected peer-reviewed publications (in chronological order).
(Publications selected from over 500 peer-reviewed publications)
Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, and Champlin RE: Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma. J Natl Cancer Inst 92(3):225-233, 2000.
Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Warner DL, Payne JY, Tucker SD, Bartolomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC: Cationic Liposome-Mediated Adenovirus Type 5 E1A Gene Transfer to Human Breast and Ovarian Cancer Cells and Its Biological Effects: A Phase I Clinical Trial. J Clin Oncol 19:3422-3433, 2001.
Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer HM, Buchholz TA, and Hortobagyi GN: Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes. J Clin Oncol 23(1):41-48, 2004.
Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN: Significantly Higher Pathological Complete Remission Rate After Neoadjuvant Therapy with Trastuzumab, Paclitaxel and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer. J Clin Oncol 23(16):3676-3685, 2005
Gonzalez-Angulo AM, Sahin A, Krishnamurthy S, Yang Y, Kau SW, Hortobagyi GN, Cristofanilli M: Biologic Markers in Axillary Node-Negative Breast Cancer: Differential Expression in Invasive Ductal Carcinoma versus Invasive Lobular Carcinoma. Clin Breast Cancer 7(5):396-400, 2006.
Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, and Hortobagyi GN: Neoadjuvant Therapy with Paclitaxel Followed by 5-Fuorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen. Clin Cancer Res 13(1):228-233, 2007.
Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M: Kinetics of Serum HER-2/neu Changes in Patients with HER-2-Positive Primary Breast Cancer After Initiation of Primary Chemotherapy. Cancer 109(3):496-501, 2007. [Epub ahead of print on December 5, 2006].
Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN: Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients with Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine. J Clin Oncol 2007. [Epub ahead of print on July 2, 2007].
Badgwell BD, Giordano SH, Duan ZZ, Fang S, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, Babiera G: Mammography Before Diagnosis Among Women Age 80 and Older with Breast Cancer. J Clin Oncol 2008. [Epub ahead of print on April 21, 2008] PMID: 18427152
Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS: Limits of Observational Data in Determining Outcomes from Cancer Therapy. Cancer 2008. [Epub ahead of print on April 21, 2008] PMID: 18428196
Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF and Hortobagyi GN: The Frequency and Risk Factors Associated with Osteonecrosis of the Jaw in Cancer Patients Treated with Intravenous Bisphosphonates. J Bone Min Res 2008. [Epub ahead of print on February 5, 2008] PMID: 18435574
Bristol IJ, Woodward WA, Strom EA, Cristofanilli M, Domain D, Singletary SE, Perkins GH, Oh JL, Yu TK, Terrefe W, Sahin AA, Hunt KK, Hortobagyi GN, Buchholz TA: Locoregional Treatment Outcomes After Multimodality Management of Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys 2008. [Epub ahead of print on April 24, 2008] PMID: 18439768
Srokowski TP, Fang S, Duan Z, Buchholz TA, Hortobagyi GN, Goodwin JS, Giordano SH: Completion of Adjuvant Radiation Therapy Among Women With Breast Cancer. Cancer 2008. [Epub ahead of print on April 28, 2008] PMID: 18442124
Tordai A, Wang J, Andre F, Liedtke C, Yan K, Sotiriou C, Hortobagyi GN, Symmans FW and Pusztai L: Evaluation of Biological Pathways Involved in Chemotherapy Response in Breast Cancer. Breast Cancer Res 2008. [Epub ahead of print on April 29, 2008] PMID: 18445275
Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, Meric-Bernstam F, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM; for the Inflammatory Breast Cancer Research Group: Prognostic Significance of HER-2 Status in Women with Inflammatory Breast Cancer. Cancer 112(9):1905-1911, 2008. [Epub ahead of print February 25, 2008]. PMID: 18300243
C. Research Support
1 P50 CA116199-01 Hortobagyi (PI)
9/23/2005 – 8/31/2010
NIH/NCI - UTMDACC SPORE in Breast Cancer
The goal of this project is to foster interactive, multi-specialty translational research in breast cancer diagnosis, prevention and treatment.
Role: PI
2P30 CA016672 28(PP-4) Hortobagyi (PI)
DHHS-NIH-NCI
Cancer Center Support (Core) Grant-Project 4-Breast Cancer Program
The major goal of this project is to establish the research infrastructure and organization for the Breast Cancer Research Program at The University of Texas M. D. Anderson Cancer Center.
Susan G. Komen Breast Cancer Foundation
Interdisciplinary Breast Cancer Fellowship Program
Hortobagyi (Program Director)
The major goal of this grant is to provide interdisciplinary training to physicians specializing in all aspects of the management of breast diseases.
Role: Program Director
ASCO Career Development Award Gonzalez-Angulo (PI)
The PI3K/PTEN/AKT Signal Transduction Cascade as a Predictor for Response to Therapy and Therapeutic Target in Breast Cancer
Goal: To study the role of the PI3K/PTEN/AKT Signal Transduction Cascade in breast cancer as a classifier, predictor of response, and target for preoperative therapy.
Role: Mentor
NCI: 1 U10 CA105409 Lippman (PI)
U10 Full Member Application Affiliated with SWOG
7/26/04-12/31/09
Goal: Development of Studies
NCI: DHHS-NIH: 1 K23 CA12199401 (Gonzalez-Angulo (PI)
The PI3K/PTEN/AKT Signal Transduction Cascade in Breast Cancer
7/1/06-6/30/11
Goal: To study the relationship of P13K, PTEN, and SKT signal transduction in breast cancer.
Role: Consultant
The Breast Cancer Research Foundation: Breast Cancer-Targeted Therapy by Endostatin-Cytosine Deaminase Fusion Protein. (G.N. Hortobagyi, PI)
10/1/2008 – 9/30/2009
Past Support
DHHS–NIH-National Cancer Institute: 3 P50 CA116199-02S1 Bondy (Project PI)
(SPORE Supplement)
9/28/06 – 8/31/2008
Comparative Study of Breast Cancers and their Risk Factors Among Mexican Women in Mexico and the U.S.
Goal: Study the difference of risk factors between Mexican American women in the US and Mexico.
Role: SPORE PI
Entertainment Industry Foundation: EIF/WCRF Breast Cancer Biomarker Discovery Project.
P.I.: Leyland Hartwell
10/5/07 – 10/4/08
Role: Steering Committee Member: October 5, 2007 through October 4, 2008.
NCI: DHHS-NIH (1 K01 CA118174 01) Nahta (PI)
HER-2/IGF-1R Crosstalk and Herceptin Resistance
8/1/06 – 2/15/08
Goal: Study the relationship of HER-2/IGF-1R and Herceptin Resistance.
Role: Investigator
DAMD17-02-1-0694 01 Hortobagyi (PI)
USAMRMC-DOD Breast Cancer Research Program
Breast Cancer Center of Excellence: Development of Targeted Therapy Strategies for Breast Cancer.
The major goals of this project are to develop an interactive, multidisciplinary center that will combine expertise in molecular biology, novel animal models and clinical trials expertise to expedite the discovery and development of novel targeted therapies.
DAMD17-02-1-0456 1 Pusztai (PI)
4/012002 –4/31/2006
USAMRMC "The Role of Sigma Receptor in Breast Cancer"
The major role of this grant is to study and discover the role of sigma receptors in breast cancer.
1RO1CA89608-O1A1 Bondy (PI)
Epidemiologic and Genetic Determinants of Breast Cancer Survival
The major goals of this project are to understand the influence of genetic and environmental influences on survival of patients with breast cancer.
Eduardo Cazap, MD, PhD (Argentina)
Past President, Union for International Cancer Control (UICC-Geneva)
Founder and First President, Latin American & Caribbean Society of Medical Oncology (SLACOM)
Past President, Argentine Association of Clinical Oncology
Eduardo Cazap MD, PhD is the founder and first President of the Latin American & Caribbean Society of Medical Oncology (SLACOM) since 2004 and in 2008 was elected by the General Assembly of the Union for International Cancer Control (UICC-Geneva) as President for the 2010-2012 period. In 2009 he was elected Board Member of the American Society of Clinical Oncology (ASCO-Alexandria), representing the international members. In September 2010 was nominated by the Argentinean government member of the Board of Directors of the newly created National Cancer Institute of Argentina.
After graduating in 1972 as a medical doctor from the University of Buenos Aires in his native city, Buenos Aires, Dr. Cazap was resident in Internal Medicine and then specialist in medical oncology at the Military Central Hospital and the Universidad del Salvador. He also completed fellowships at Strong Memorial Hospital, Rochester, New York and the Lombardi Cancer Center at Georgetown University, Washington, D.C. He was also fellow of the American Cancer Society in 1985.
Following his role as Principal Investigator of the Collaborative Cancer Research Treatment Program (PAHO-NCI) in 1984, he became Professor of Clinical Oncology at the Universidad del Salvador (1984-98) and then Professor of Medical Oncology at the Universidad Católica Argentina (1988-2000).
As well as having published over 170 papers, he has held many prominent positions in the medical arena, including Medical Director of the Instituto Dr. Estevez, Buenos Aires (1985-99) and representing Latin America at the European Society of Medical Oncology (ESMO), Lugano, Switzerland. He was President of the Argentine Association of Clinical Oncology (AAOC) in 1996-98 and 2000-02. In 2000, he was signatory of the Charter of Paris against Cancer. He is also a member of the Developing Countries Task Force for ESMO since 2002. Dr. Cazap was a member of the 2006 and 2008 UICC World Congress Program Planning Executive Committee and he is also an active member of ASCO, was Chairman of the International Affairs Committee, is member of the Cancer Prevention Committee and is member of the Board of Directors.
Dr. Cazap's main areas of research and interest are cancer prevention, breast and cervical cancer, independent clinical research and global cancer control.
He has also performed several collaborative and advisory programs with World Health Organization (WHO-Geneva) and Pan American Health Organization (PAHO-Washington).
Dr. Cazap also serves as Chairman of the Executive Committee of the Breast Health Global Initiative (BHGI) which is co-sponsored by the Fred Hutchinson Cancer Research Center and Susan G. Komen for the Cure®. BHGI strives to develop and implement Guidelines for International Breast Health and Cancer Control for low- and middle-income countries.
One of Dr. Cazap's most relevant ongoing projects is as Chair of the International Clinical Trials Working Group (ICTWG), a joint effort of ASCO and NCI-US, for the improvement of independent clinical cancer research at the international level.
He is also leading the International Cancer Prevention Stakeholders Group, under the umbrella of UICC and the support of ASCO. This initiative has been developed for international activities in cancer prevention gathering various organizations (UICC, ASCO, ESMO, AACR, ACS, WHO and others) in a common and coordinate strategy for the improvement of global cancer control.
Dr. Cazap was also elected President of the UICC World Cancer Congress that was held in Montreal, Canada, in 2012.
Yuko Kitagawa, MD, PhD, FACS (Japan)
Professor and Chairman, Department of Surgery, Keio University, School of Medicine
Director, Keio Cancer Center
Vice President, Keio University Hospital (Tokyo)
Dr. Kitagawa is a surgical oncologist and clinical and translational researcher, primarily in the areas of gastrointestinal cancers. He is a chair of the Japan Esophageal Oncology Group and working as a principal investigator for several important nationwide clinical studies, including sentinel node mapping for gastric cancer and multimodal treatment for esophageal cancer. He is an editor-in-chief of Gastric Cancer, the official journal of the Japan Gastric Cancer Association and International Gastric Cancer Association. He is also serving as a chairman of the Japan chapter of the International Society of Surgery (ISS) / Société Internationale de Chirurgie (SIC).
Alexander M.M. Eggermont, MD, PhD (France)
General Director, Cancer Institut Gustave Roussy, Villejuif-Paris
President, European Academy of Cancer Sciences
A melanoma specialist, Dr. Alexander Eggermont is the current president of the European Academy of Cancer Sciences and is past president of the European CanCer Organisation (ECCO) and the European Organisation for Research and Treatment of Cancer (EORTC). He is also a past member of the board of directors for the American Society of Clinical Oncology. Dr. Eggermont was a professor of surgical oncology at Erasmus University Medical Center in Rotterdam, Netherlands, and is the author or coauthor of more than 600 peer-reviewed publications, book chapters and monographs.
John F. Thompson, MD, FRACS, FACS (Australia)
Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney
Senior Surgeon, Melanoma Institute Australia
Chairman, Cancer Council Australia Melanoma Guidelines Working Party
Dr.John Thompson is a Senior Surgeon at Melanoma Institute Australia (formerly the Sydney Melanoma Unit), one of the largest melanoma treatment and research centres in the world. He is involved in many aspects of translational and clinical melanoma research, and has published widely on melanoma-related topics. He is chairman of the working party that produced the Australian and New Zealand Clinical Practice Guidelines for the Management of Cutaneous Melanoma. He is Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney, and the Past-President of the International Sentinel Node Society.
Jaime G. de la Garza, MD (Mexico)
Director Emeritus, Instituto Nacional de Cancerología, Mexico
Advisor, Consejo Mexicano de Oncología
Former Director General, Instituto Nacional de Cancerología, Mexico
Founder and Past President, Mexican Oncology Board
BORN in Monterrey, N.L.Mexico, December 12, 1934.
STUDIES: Medical Doctor, Universidad Autónoma de Nuevo León-Monterrey,Mexico, 1952-1958;
Postgraduate in Internal Medicine and Medical Oncology in South Texas Medicine School; at San Antonio Texas. USA, 1959-1964;
Mayo Clinic, Rochester, Minnesota, 1965-1966.
Educational Council For Foreign Medical Graduate Evanston Illinois, USA. 1962;
Senior Researcher "F" in the Institutos Nacionales de Salud,
Level II National Researcher of the Sistema Nacional de Investigadores of the CONACYT,
Doctor Honoris Causa granted by the Universidad Autónoma de Puebla,
Doctor in Medicine-Honoris Causa., Universidad Autónoma de Nuevo León.(Monterrey N.L.)
First representative of Latin America in the "Reunion Mundial de la Guerra contra el Cancer 2000" held in the Versailles Palace (Paris, France).
"11th.Cino del Duca Award,Achievement in Cancer Research" 14th. International Congress Anti-Cancer, feb. 4,2003. Versailles Palace (Paris, France).
PREVIOUS POSITIONS:
Former President of the Mexican Oncology Society(1980-81) and Founder and president of the Mexican Oncology Board(1998-2000),
Former General Director of the Instituto Nacional de Cancerología-Mexico(1993-2003),
Executive Secretary Science Advisory Council for the Presidency of the Mexican Republic
Clinical Research Investigator at the Instituto Nacional de Cancerología-Mexico,
Member of the Academic Committee of the ICAT-PARIS Courses(1989-2008),
Advisor of the Consejo Mexicano de Oncología,
Member of the H. Administration Council of the Universidad Autónoma de Nuevo León,
Editorial Board of the Journal of the Instituto Nacional de Cancerología
Academic Reviewer of the Research Program of the Consejo Nacional de Ciencia y Tecnología, CONACYT,
Level II National Researcher of the "Sistema Nacional de Investigadores of the CONACYT",
Reviewer Member of more than 10 International Journals,
Member of the International Affairs Committee of ASCO. 2004-2007. (Chair elect 2005) American Society of Clinical Oncology.(ASCO )
Member and founder of "Sociedad Lationamericana y del Caribe de Oncologia Medica" (SLACOM)
Miembro de ESMO Developing Countries Task Force. 2005.
SCIENTIFIC PRODUCTION:
Author of more than 160 works in national and international arbitrated journals, chapters in book;
Lecturer of more than 1000 national and international lectures, among others.
MEDICAL SOCIETIES:
Academia Nacional de Medicina,Mexico,
Academia Mexicana de Cirugía,
Academia Mexicana de Ciencias
American Society of Clinical Oncology;(ASCO)
Alumni Association Mayo Graduate School of Medicine, University of Minnesota, USA
Soc.Latinoamericana y del Caribe de Oncologia Medica(SLACOM)
European Society Medical Oncology(ESMO) among others.
Yi-Long Wu, MD (China)
Vice President, Guangdong General Hospital
Director, Guangdong Lung Cancer Institute
President, Chinese Society of Clinical Oncology
Dr.Wu graduated from Sun Yat-sen University of Medical Sciences in 1982 and completed his thoracic surgery training in Germany in 1989. His main research interests include multidisciplinary synthetic therapy on lung cancer and evidence-based medicine in oncology. As vice-president of the Guangdong General Hospital & Guangdong Academy of Medical Sciences and a director of Guangdong Lung Cancer Institute, he also serves as president of the Chinese Society of Clinical Oncology(CSCO) and the president of the Chinese Thoracic Oncology Group (C-TONG).
Dr. Wu is leading the Chinese lung cancer field and has been a principle investigator or co-principle investigator in more than 90 multicenter clinical trials.A contributor to 20 books oncancer, he has also published more than 300 articles in peer-reviewed journals. He also serves on the editorial boards of Cancer Letters, Annals of Surgical Oncology, Lung Cancer Management, International Journal of Biological Marker and General Thoracic and Cardiovascular Surgery. He is editor-in-chief of Journal of Evidence-based Medicine, Journal of Thoracic Oncology (Chinese Edition) and Oncologist (Chinese Edition).
Dr. Wu also serves as president of the International Chinese Society of Thoracic Surgery (ICSTS) and is a Fellow of the American College of Surgeons.
Patient Advisory Board Members:
Alan J. Balch, PhD
CEO, National Patient Advocate Foundation &
Patient Advocate Foundation
Now serving as CEO of NPAF and PAF, Dr. Alan Balch most recently was vice president of the Preventive Health Partnership, a collaboration between the American Cancer Society, the American Diabetes Association, and the American Heart Association. He is also the past executive director of Friends of Cancer Research. Balch volunteers as a member of the board of directors for the Center for a New American Dream and the Colorectal Cancer Coalition. He holds a doctorate in environmental studies and a master's in environmental sciences.
Lillie D. Shockney, RN, BS, MAS, ONN-CG
University Distinguished Service Professor of Breast Cancer, Professor of Surgery and Oncology, Johns Hopkins University School of Medicine
Former Adm Director, Johns Hopkins Breast Center
Former Director, Johns Hopkins Survivorship Programs
Lillie D. Shockney, is an active clinical researcher with a focus on quality of life issues for survivors. She has written eight books and many articles on the subject of breast cancer. She is the co-founder and vice president of "Mothers Supporting Daughters with Breast Cancer." She serves as Ask an Expert for several breast cancer websites including Yahoo.com and the Johns Hopkins Breast Center's website, and she chairs the National Consortium of Breast Centers QI Task Force.
Linda Bohannon, RN, BSN, MSM
President & Chief Executive Officer, Vital Strategic Insights
Linda Bohannon has extensive experience as an oncology nurse, a healthcare administrator, a pharmaceutical industry leader, and is an expert in policy, regulatory, and communications issues. Her previous roles include CEO of the Cancer Support Community global headquarters, Executive Director of St. Vincent Cancer Care, and Sr. Director of Advocacy and Professional Relations for Eli Lilly and Company, Lilly Oncology. Working a decade or more in each of these sectors, Linda brings a well-rounded perspective to her work and those she serves.
A sought-after speaker, Linda has raised important issues across many areas. She has testified before the House of Representatives Committee on Energy & Commerce regarding medical product manufacturer communication, served as a panelist at The Atlantic's People v. Cancer Summit, and advocated for the elevation of the patient voice at Union for International Cancer Control and others.
Linda serves in a variety of advisory roles in the local and national cancer community and as a part of nonprofit and for-profit companies.
Doug Ulman
CEO, Pelotonia
Doug Ulman is a three-time cancer survivor and national cancer survivorship advocate. Formerly the president and chief executive officer of the LIVESTRONG Foundation, he also founded the Ulman Cancer Fund for Young Adults, a nonprofit organization to provide support, education and resources to young adults, their families and friends affected by cancer. As CEO of Pelotonia, he oversees the group's objective to fund life-saving cancer research through its three-day experience that includes a weekend of cycling, entertainment and volunteerism. Pelotonia is able to direct 100 percent of every rider-raised dollar to cancer research at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute. Ulman also serves as chairman of the National Cancer Institute Director's Consumer Liaison Group and sits on the Google Health Advisory Board. He is a member of the American Society of Clinical Oncology and co-founder of the LIVESTRONG Young Adult Alliance.
Brian Garofalo
President, Patient Alliances, LLC
Brian Garofalo has over twenty years of management experience with three major pharmaceutical and bio-pharmaceutical companies. He has been an effective liaison for his industry and patient communities in the disease areas of Cancer, HIV/AIDS, Diabetes and Cardiovascular. Garofalo's advocacy career has focused mainly on ensuring patients and physicians have the ability to maintain access to innovative therapies. He himself is a cancer survivor and is widely sought for his experience and passion for the patient – understanding that whatever the issue may be, solutions are more plausible if a patient-centric approach is maintained. He has started his own consulting company, Patient Alliances, LLC - providing strategic healthcare alliances and solutions for a number of diversified clients.
Armin D. Weinberg, PhD
Clinical Professor, Baylor College of Medicine
Adjunct Professor, Rice University
Faculty Affiliate, Texas A&M Center for Population Health and Aging
Co-Founder, Intercultural Cancer Council
Dr. Weinberg is a Clinical Professor at Baylor College of Medicine (Medicine), Adjunct Professor at Rice University (Kinesiology & Human Performance) and Faculty Affiliate of the Texas A&M Center for Population Health and Aging (CPHA).
He began his career at Baylor College of Medicine in 1975 as Director of the Education Division of the first National Cardiovascular Research and Demonstration Center funded by NHLBI and from 1987 until 2011 headed the Chronic Disease Research Center. By broadening his work to include other chronic diseases including cancer he focused on translating discoveries in prevention, screening, and control activities to state and national initiatives exemplified by his role as the Co-founder of the Intercultural Cancer Council.
He was a founder of the International Consortium for Research on the Health Effects of Radiation, in response to the Chernobyl nuclear accident and has spearheaded international partnerships in the Ukraine, Kazakhstan, Azerbaijan, Russia, and Israel. Dr. Weinberg and the late William "Jack" Schull, Professor Emeritus of Human Genetics at The University of Texas Health Science Center at Houston, collaborated to establish a new family of collections under the umbrella of "Radiation Effects and Events." This new collecting area at the John P. McGovern Historical Center at The TMC Library, is building on the "Atomic Bomb Casualty Commission" collections and will encompass other areas where ionized radiation has affected our world.
As Principal Investigator of the Eliminating Disparities in Clinical Trials Project (EDICT), he led a research study designed to address the problems and find workable solutions to recruiting and retaining populations that are underrepresented in clinical trials. After retiring as a Full Professor at Baylor College of Medicine he served as the CEO of Life Beyond Cancer Foundation from 2011-2015 where he lead the development of MyHealthFinder ™ now housed at Texas A&M's School of Public Health.
Examples of other research studies that Dr. Weinberg has been involved with as a Principal Investigator or Co-Principal Investigator are, "Gulf Coast Transdisciplinary Research Recover Center for Community Health", "National DES Education Project", "Low-Fat Diet and Prostate Cancer," "Low-Fat Diet and Breast Cancer", "Specialized Program of Research Excellence in Prostate Cancer", "Cancer Genetics-Physician & Patient Issues Related to Inherited Cancers","Stability of Cholesterol Levels Over Time Among Children" and "Cardiovascular Family Risk is Modifiable: A Multiple Community Study"
Dr. Weinberg currently serves as a board member of the Intercultural Cancer Council, Community of Practice (CoP) for Vulnerable Populations for National Center for Medical Education Development & Research,The Schull Institute Advisory Board, National Hispanic Life Sciences Society, Texas Life Science Foundation, member of the Comprehensive Cancer Control National Partnership, the Texas Medical Association Subcommittee on CME Accreditation and The TMC Library Archives Committee.
Journal editorial and review activities include Frontiers Public Health, Journal of Cancer Education, Cancer Management and Research, Journal of Medical Internet Research, PLOS ONE, American Journal of Preventive Medicine and the Patient Advisory Board, Patient Resource Cancer Guide. Dr. Weinberg also continues to serve on grant review committees including those for the National Institutes of Health and occasionally the California Breast Cancer Research Program.
He was a founding member of the board of C-Change: Collaborating to Conquer Cancer and inaugural recipient of The George & Barbara Bush Collaboration Award. Examples of other recognition include the Past board and leadership experience include The National Association of Social Worker Foundation, Life Beyond Cancer Foundation, Advisory Board of Molecular Health, USA, The Texas Hadassah Medical Research Foundation, Volunteer Houston, UTMB School of Allied Health Sciences Advisory Council, Cancer Support Community M.A.P. Project Advisory Council, Redes En Acción National Center Steering Committee and the Cancer Alliance of Texas.
Awards in recognition of his interest in and achieving impact in the community include the American Cancer Society – Humanitarian Award, the American Jewish Committee: Academicians Award, National Patient Advocate Foundation - National Health Care Hero Award, State of Israel Bonds: Maimonides Award, Susan G. Komen Breast Cancer Research Foundation, Jill Ireland Award behalf of the ICC, Texas Cancer Council: Gib Lewis Award for Public Education, Texas School Health Association Distinguished Service Award and Volunteer Houston's Lifetime Member Award.
Division Director, Educational Meetings, American Society of Clinical Oncology
Lisa Greaves is the Division Director of Educational Meetings at the American Society of Clinical Oncology. She is a long-term survivor of breast cancer who connects with newly diagnosed patients through community organizations and speaking at cancer awareness events. Greaves is a graduate of the National Breast Cancer Coalition Fund's Project LEAD Institute. She serves on the Board of Directors of the Breast Cancer Care Foundation, a DC-based nonprofit that supports residents who are underserved, uninsured, or otherwise have insufficient financial resources for breast health care. Greaves has explored her own cancer journey through photography and poetry.
Home | About Us | Privacy Policy | Terms & Conditions | Disclaimer | Site Map © Copyright 2022 Patient Resource LLC. All rights reserved.


text:
Suspenseful Shows for Fans of Peaky Blinders
If you're a die-hard fan of Peaky Blinders, then you've come to the right place. The shows in this list are filled with excitement and suspense. We're sure you'll love every last one of them.
2014 | Drama, Sci-Fi & Fantasy, Horror
Some of literature's most terrifying characters, including Dr. Frankenstein, Dorian Gray, and iconic figures from the novel Dracula are lurking in the darkest corners of Victorian London. Penny Dreadful is a frightening psychological thriller that weaves together these classic horror origin stories into a new adult drama.
2016 | Drama
A complex drama about power politics in the world of New York high finance. Shrewd, savvy U.S. Attorney Chuck Rhoades and the brilliant, ambitious hedge fund king Bobby "Axe" Axelrod are on an explosive collision course, with each using all of his considerable smarts, power and influence to outmaneuver the other. The stakes are in the billions in this timely, provocative series.
2015 | Documentary, Crime, History
A docudrama series chronicling some of America's most notorious mobsters, each season dealing with a different city/region.
2017 | Drama, Western
A ruthless outlaw terrorizes the West in search of a former member of his gang, who's found a new life in a quiet town populated only by women.
2015 | Crime, Drama
Six years before Saul Goodman meets Walter White. We meet him when the man who will become Saul Goodman is known as Jimmy McGill, a small-time lawyer searching for his destiny, and, more immediately, hustling to make ends meet. Working alongside, and, often, against Jimmy, is "fixer" Mike Ehrmantraut. The series tracks Jimmy's transformation into Saul Goodman, the man who puts "criminal" in "criminal lawyer".

redpajama_set_name: RedPajamaCommonCrawl


Wishbone Mini-Flip is a multi-functional walker, rocker, ride-on. Three exciting experiences teach balance, motor skills and coordination.
Wishbone Mini-Flip, is brilliantly simple and built to last.
With its innovative flipping mechanism, Wishbone Mini-Flip transforms from rocker to baby walker to ride-on in seconds. Fully assembled in just minutes, Mini-Flip sports racing red scooter wheels for stability. Wishbone Mini-Flip is Flip's little cousin, smaller, lower and with greater stability - perfect for baby's first steps.